Evidence map›Paper›PMID 35447104›Full record

ArticleExperimental cell research2022

Physiological levels of poly(ADP-ribose) during the cell cycle regulate HeLa cell proliferation.

Sachiko Yamashita, Masakazu Tanaka, Chieri Ida, Kenichi Kouyama, Setsu Nakae, Taisuke Matsuki, Masataka Tsuda, Tsuyoshi Shirai, Kazuo Kamemura, Yoshisuke Nishi and 2 more

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental cell research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Sachiko YamashitaFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Masakazu TanakaJoint Research Center for Human Retrovirus Infection, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima, 890-8544, Japan.
Chieri IdaDepartment of Applied Life Sciences, College of Nagoya Women's University, Nagoya-shi, Aichi, 467-8610, Japan.
Kenichi KouyamaFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Setsu NakaeFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Taisuke MatsukiFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Masataka TsudaProgram of Mathematical and Life Sciences, Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, 739-8526, Japan.
Tsuyoshi ShiraiFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Kazuo KamemuraFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Yoshisuke NishiFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan.
Joel MossPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892-1590, USA.
Masanao MiwaFaculty of Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama, Shiga, 526-0829, Japan. Electronic address: m_miwa@nagahama-i-bio.ac.jp.
Nagahama Institute of Bio-Science and Technology · JPHiroshima University · JPKagoshima University · JPNagoya Women's University · JPNational Institutes of Health · US

Funding

ADP-ribosylation CyclesZIAHL000659 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI MOSS, JOEL · 2009 to 2025
$29.8M
ADP-RIBOSYLATION CYCLESZ01HL000659 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI MOSS, JOEL · 1993 to 2008
$2.1M
Intramural NIH HHS Z01 HL000659
6 · The paper itself

Abstract

Protein targets of polyADP-ribosylation undergo covalent modification with high-molecular-weight, branched poly(ADP-ribose) (PAR) of lengths up to 200 or more ADP-ribose residues derived from NAD

Indexed as

Poly Adenosine Diphosphate RibosePoly(ADP-ribose) Polymerase InhibitorsCell CycleCell DivisionHeLa CellsHumansNADPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) PolymerasesNADPoly Adenosine Diphosphate RibosePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesADP-RibosylationCell cycleCell proliferationNAD(+)PolyADP-ribosylationS phase

Identifiers

PMID35447104
PMCPMC10009817
OpenAlexW4224267677

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read99
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.